IQ EQ FUND MANAGEMENT IRELAND Ltd Has $2.05 Million Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Key Points

• IQ EQ FUND MANAGEMENT IRELAND Ltd increased its stake in Recursion Pharmaceuticals by 93.2%, acquiring an additional 186,767 shares during the first quarter.
• Research analysts have given the stock an average rating of "Hold" with a consensus price target of $7.00, reflecting mixed sentiment from the investment community.
• Recursion Pharmaceuticals' latest earnings report showed a Q1 loss of ($0.50) EPS, missing estimates, alongside revenue of $14.75 million compared to the forecast of $18.12 million.

IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 93.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 387,237 shares of the company's stock after buying an additional 186,767 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd owned approximately 0.10% of Recursion Pharmaceuticals worth $2,048,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. GAMMA Investing LLC boosted its position in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after purchasing an additional 2,026 shares during the period. NewEdge Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after buying an additional 2,387 shares during the period. GF Fund Management CO. LTD. acquired a new position in Recursion Pharmaceuticals in the 4th quarter valued at $54,000. San Luis Wealth Advisors LLC bought a new position in Recursion Pharmaceuticals in the 1st quarter worth $54,000. Finally, ADG Wealth Management Group LLC bought a new position in Recursion Pharmaceuticals in the 1st quarter worth $55,000. Institutional investors own 89.06% of the company's stock.

Analysts Set New Price Targets

RXRX has been the topic of several research analyst reports. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $7.00.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX traded down $0.02 during mid-day trading on Friday, hitting $5.40. The company had a trading volume of 9,469,376 shares, compared to its average volume of 25,190,070. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36. The firm has a market cap of $2.19 billion, a P/E ratio of -3.03 and a beta of 0.93. The business's 50-day simple moving average is $5.38 and its 200-day simple moving average is $5.92. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 4.11.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The firm had revenue of $19.10 million during the quarter, compared to analyst estimates of $15.38 million. During the same period last year, the company earned ($0.40) EPS. The company's revenue was up 33.3% on a year-over-year basis. As a group, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.